Outcomes from targeted axillary lymph node dissection after neoadjuvant chemotherapy for breast cancer in a safety-net medical center. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Results of the prospective randomized controlled trial VOG-01: Neoadjuvant endocrine therapy ribociclib + fulvestrant + GnRH-a versus chemotherapy 4 AC + 4 T for early HR+/HER2-negative breast cancer ...

91.6% of people treated with the Perjeta-based regimen were alive at ten years versus 89.8% of those treated with Herceptin, chemotherapy, and placebo (hazard ratio [HR]=0.83, 95% CI: 0.69-1.00, ...

Sara M. Tolaney, MD, MPH, highlights a transformative year for breast cancer research at this year’s ASCO Annual Meeting.

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running ...

AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer: Cambridge, UK Thursday, May ...

Enhertu (fam-trastuzumab deruxtecan-nxki) followed by Taxol (paclitaxel), Herceptin (trastuzumab) and Perjeta (pertuzumab), also known as THP ... which is assessing neoadjuvant Enhertu monotherapy or ...

After ten years, the risk of death was reduced by 17% for people treated with Perjeta ® (pertuzumab), Herceptin ® (trastuzumab ... Use prior to surgery (neoadjuvant treatment) in adults with ...

trastuzumab, and pertuzumab (THP), significantly improved pathologic complete response (pCR) rates compared to the current standard of care in the neoadjuvant treatment of high-risk, locally ...

The DESTINY-Breast11 trial (ClinicalTrials.gov Identifier: NCT05113251) evaluated the efficacy and safety of trastuzumab deruxtecan as a neoadjuvant therapy in 927 participants aged 18 years and ...